Open AccessROS1 rearrangement and response to crizotinib in Stage IV non-small cell lung cancer
Author(s) -
Moushumi Suryavanshi,
Manoj Kumar Panigrahi,
Dushyant Kumar,
Haristuti Verma,
Mumtaz Saifi,
Bharti Dabas,
Ullas Batra,
D.C. Doval,
Anurag Mehta
Publication year - 2017
Publication title -
lung india
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 25
eISSN - 0974-598X
pISSN - 0970-2113
DOI - 10.4103/lungindia.lungindia_116_17
Subject(s) - crizotinib , ros1 , medicine , anaplastic lymphoma kinase , adenocarcinoma , gene rearrangement , lung cancer , lung , oncology , fluorescence in situ hybridization , pathology , cancer research , cancer , gene , biochemistry , chemistry , malignant pleural effusion , chromosome
The frequency of ROS1 rearrangement in non-small cell lung cancers has been reported from 1.6% to 2.3%.